Bob:  Here is the result of a MEDLINE search on Wellbutrin (Bupropion)
and Parkinson's Disease.  This is all there was.  The last article is an
animal model only.
 
--------------------------------------------------------------------
 
?find parkinson and bupropion
            9892  PARKINSON
             272  BUPROPION
      S1       5  PARKINSON AND BUPROPION     (Wellbutrin)
 
?type s1/l/all
 
 1/L/1
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1995 Knight-Ridder Info. All rts. reserv.
 
08788150   94103150
  Acute  delirium  and parkinsonism in a bupropion-treated liver
transplant
recipient [letter]
  Strouse TB; Salehmoghaddam S; Spar JE
  J  Clin  Psychiatry (UNITED  STATES)   Dec  1993,  54 (12) p489-90,
ISSN
0160-6689   Journal Code: HIC
  Languages: ENGLISH
  Document type: LETTER
  JOURNAL ANNOUNCEMENT: 9404
  Subfile:   INDEX MEDICUS
  Tags: Case Report; Human; Male
  Descriptors:   *Buspirone--Adverse   Effects--AE;  *Delirium
--Chemically
Induced--CI;   *Liver   Transplantation;  *Parkinson  Disease,
Symptomatic
--Chemically  Induced--CI;  Depressive Disorder--Drug Therapy--DT;
Dystonia
--Chemically Induced--CI; Middle Age
  CAS Registry No.: 36505-84-7   (Buspirone)
 
 1/L/2
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1995 Knight-Ridder Info. All rts. reserv.
 
08138379   92276379
  Falling backward in two elderly patients taking bupropion.
  Szuba MP; Leuchter AF
  Department  of  Psychiatry  and  Biobehavioral  Sciences,  University
 of
California, Los Angeles School of Medicine.
  J  Clin  Psychiatry (UNITED  STATES)   May  1992,  53  (5)  p157-9,
ISSN
0160-6689   Journal Code: HIC
  Contract/Grant No.: T32MH17140, MH, NIMH
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE
  JOURNAL ANNOUNCEMENT: 9209
  Subfile:   INDEX MEDICUS
  BACKGROUND:  Bupropion,  a  novel  antidepressant,  has  been reported
to
produce  fewer  adverse  effects than the tricyclic antidepressants. It
has
relatively  weak  effects  on  norepinephrine  and  serotonin  reuptake
but
possesses  significant  dopamine  agonist  and  reuptake  blocking
effects.
METHOD: The case histories of two geriatric patients treated with
bupropion
for  major  depression  are presented. RESULTS: Both patients
experienced a
previously   unreported   side  effect--falling  backward--associated
with
bupropion  use. Orthostatic hypotension and vertigo are not consistent
with
the patients' histories. Both patients manifested other symptoms
consistent
with parkinsonian syndrome. CONCLUSION: This side effect, apparently
unique
to  bupropion  among  antidepressants, may be mediated through
dopaminergic
effects in the basal ganglia. Clinicians should be alert to these
potential
problems in the geriatric population.
  Tags: Case Report; Female; Human; Support, U.S. Gov't, P.H.S.
  Descriptors:  *Bupropion--Adverse Effects--AE; *Depressive
Disorder--Drug
Therapy--DT; *Dyskinesia, Drug-Induced--Etiology--ET; *Posture; Age
Factors
;  Aged; Basal Ganglia Diseases--Chemically Induced--CI; Parkinson
Disease,
Symptomatic--Complications--CO
  CAS Registry No.: 34841-39-9   (Bupropion)
 
 1/L/3
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1995 Knight-Ridder Info. All rts. reserv.
 
07539209   91058209
  Bupropion and delirium [letter] [see comments]
  Liberzon I; Dequardo JR; Silk KR
  Am  J  Psychiatry (UNITED  STATES)   Dec  1990,  147 (12) p1689-90,
ISSN
0002-953X   Journal Code: 3VG
  Comment in  Am J Psychiatry 1991 Aug;148(8):1101-2
  Languages: ENGLISH
  Document type: LETTER
  JOURNAL ANNOUNCEMENT: 9103
  Subfile:   AIM; INDEX MEDICUS
  Tags: Case Report; Human; Male
  Descriptors:   *Antidepressive   Agents--Adverse  Effects--AE;
*Delirium
--Chemically   Induced--CI;   *Propiophenones--Adverse  Effects--AE;
Aged;
Amantadine--Adverse    Effects--AE;     Amantadine--Therapeutic
Use--TU;
Antidepressive   Agents--Therapeutic  Use--TU;  Depressive  Disorder
--Drug
Therapy--DT; Drug Therapy, Combination; Parkinson Disease--Drug
Therapy--DT
; Propiophenones--Therapeutic Use--TU
  CAS  Registry  No.:  0    (Antidepressive  Agents); 0
(Propiophenones);
34841-39-9   (Bupropion); 768-94-5   (Amantadine)
 
 1/L/4
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1995 Knight-Ridder Info. All rts. reserv.
 
06806683   89108683
  Diagnosis and treatment of depression in the elderly.
  Kim KY; Hershey LA
  Department of Psychiatry, State University of New York, Buffalo.
  Int  J  Psychiatry  Med (UNITED  STATES)   1988,  18  (3)  p211-21,
ISSN
0091-2174   Journal Code: GSJ
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE; REVIEW; REVIEW, ACADEMIC
  JOURNAL ANNOUNCEMENT: 8905
  Subfile:   INDEX MEDICUS
  Depression  and  suicide are significant problems in the elderly, both
in
terms  of their severity and their prevalence. It is particularly
difficult
to  distinguish  depression  from  early  dementia, since elderly
depressed
patients  often deny mood disorder and focus on their memory problems.
This
differential  diagnostic dilemma is further complicated by the fact that
20
percent  of  Alzheimer-type  dementia  patients  have  moderate  to
severe
depression.  An even higher prevalence of depression can be seen in
elderly
patients  with  stroke  or  Parkinson's disease. Most all of the
depressive
disorders  of  the  elderly  are  amenable  to  one  form or combination
of
therapies:  pharmacologic,  electro-convulsive, or psychotherapy.
Tricyclic
antidepressants  are  often  associated  with adverse drug reactions in
the
elderly,  so alternatives such as MAO inhibitors, alprazolam, bupropion
and
psychostimulants are currently being explored in this patient
population.
(56 Refs.)
  Tags: Human
  Descriptors:  *Aged;  *Depressive Disorder--Diagnosis--DI;
Antidepressive
Agents,    Tricyclic--Adverse    Effects--AE;   Cerebrovascular
Disorders
--Complications--CO;  Dementia--Diagnosis--DI; Depressive
Disorder--Therapy
--TH; Parkinson Disease--Complications--CO
  CAS Registry No.: 0   (Antidepressive Agents, Tricyclic)
 
 1/L/5
DIALOG(R)File 154:MEDLINE(R)
(c) format only 1995 Knight-Ridder Info. All rts. reserv.
 
05774832   86075832
  Stress-induced   neurological   impairments   in   an   animal  model
 of
parkinsonism.
  Snyder AM; Stricker EM; Zigmond MJ
  Ann Neurol (UNITED STATES)   Nov 1985,  18 (5) p544-51,  ISSN
0364-5134
Journal Code: 6AE
  Contract/Grant No.: MH-00058; MH-00338; MH-20620; +
  Languages: ENGLISH
  Document type: JOURNAL ARTICLE
  JOURNAL ANNOUNCEMENT: 8603
  Subfile:   INDEX MEDICUS
  Adult  rats  were given the neurotoxin 6-hydroxydopamine (6-HDA) by
means
of  cerebrospinal  fluid to produce large dopamine-depleting brain
lesions.
Although  the  animals  behaved  normally  in their home cages, they
became
akinetic  after such treatments as glucoprivation, tail shock, and
exposure
to  severe  cold.  The  neurological  impairments  were related both to
the
extent  of  dopamine  depletion  and  to the intensity of the stress.
Drugs
known   to   enhance  dopaminergic  function  were  found  to  reverse
the
stress-induced   neurological   deficits,  while  dopaminergic
antagonists
potentiated  the  debilitating  effects of stress. After focal lesions
were
produced  by  injecting  6-hydroxydopamine  directly  into  specific
brain
regions,  stress-induced akinesia was found to correlate best with
dopamine
depletion  in  the  corpus striatum, especially the lateral portion of
that
structure.  These  and  other  findings suggest that the acute emergence
of
parkinsonian  symptoms  during  stress  may reflect extensive damage to
the
dopaminergic nigrostriatal pathway that had been concealed in a
preclinical
phase,  owing  to  compensatory  neurochemical  changes in the
dopaminergic
neurons that yet remain intact.
  Tags: Animal; Male; Support, U.S. Gov't, P.H.S.
  Descriptors:  *Dopamine--Metabolism--ME;
*Hydroxydopamines--Pharmacology
--PD;  *Parkinson  Disease,  Symptomatic--Chemically  Induced--CI;
*Stress
--Complications--CO;   Corpus   Striatum--Drug   Effects--DE;
Deoxyglucose
--Pharmacology--PD; Desipramine--Pharmacology--PD; Dose-Response
Relationsh
ip,  Drug; Injections, Intraventricular; Neural Pathways--Drug
Effects--DE;
Norepinephrine--Metabolism--ME; Pargyline--Pharmacology--PD;
Propiophenones
--Pharmacology--PD;  Rats;  Rats, Inbred Strains; Receptors,
Dopamine--Drug
Effects--DE
  CAS   Registry  No.:  0    (Hydroxydopamines);  0    (Propiophenones);
 0
 (Receptors, Dopamine); 1199-18-4   (Oxidopamine); 154-17-6
(Deoxyglucose)
;    34841-39-9      (Bupropion);    50-47-5      (Desipramine);
51-41-2
 (Norepinephrine); 51-61-6   (Dopamine); 555-57-7   (Pargyline)